Do you want to read an article? Please log in or register.
Current Best Clinical Practices - Management of Neovascular AMD
Blindness and Vision ImpairmentMacular Diseases
Related content
Macular Diseases
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial
Br J Ophthalmol.
Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR; TREX-AMD Study Group
doi: 10.1136/
COMMENTED
Macular Diseases
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL
doi: 10.1001/jamaophthalmol.
Macular Diseases
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration
Ophthalmology.
Nguyen QD, Das A, Do DV, Dugel P, Gomes A, Holz FG, Koh A, Pan C, Sepah YJ, Patel N, MacLeod H, Maurer P
doi: 10.1016/j.ophtha.2019.12.031.
COMMENTED
Macular DiseasesRetinal Diseases
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Acta Ophthalmol
Gabrielle PH, Nguyen V, Creuzot-Garcher C, Miguel L, Alforja S, Sararols L, Casaroli-Marano RP, Zarranz-Ventura J, Gillies M, Arnold J, Barthelmes D
doi: 10.1111/aos.14893
Macular Diseases
Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations
Eye (Lond)
Kodjikian L, Parravano M, Clemens A, Dolz-Marco R, Holz FG, Munk MR, Nicolò M, Ricci F, Silva R, Talks SJ, Verma RK, Zarranz-Ventura J, Zweifel SA
doi: 10.1038/s41433-021-01487-0
Macular Diseases
Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Hsu J, Patel SN, Wolfe JD, Shah CP, Chen E, Jenkins TL, Wibbelsman TD, Obeid A, Mikhail M, Garg SJ, Ho AC, Chiang A, Spirn MJ, Vander JF
doi: 10.1001/jamaophthalmol.2020.0724.
Further Publications
ADVERSE EVENTS OF THE ARGUS II RETINAL PROSTHESIS: Incidence, Causes, and Best Practices for Managing and Preventing Conjunctival Erosion
Retina.
Rizzo S, Barale PO, Ayello-Scheer S, Devenyi RG, Delyfer MN, Korobelnik JF, Rachitskaya A, Yuan A, Jayasundera KT, Zacks DN, Handa JT, Montezuma SR, Koozekanani D, Stanga PE, da Cruz L, Walter P, Augustin AJ, Chizzolini M, Olmos de Koo LC, Ho AC, Kirchhof B, Hahn P, Vajzovic L, Iezzi R Jr, Gaucher D, Arevalo JF, Gregori NZ, Grisanti S, Özmert E, Yoon YH, Kokame GT, Lim JI, Szurman P, de Juan E Jr, Rezende FA, Salzmann J, Richard G, Huang SS, Merlini F, Patel U, Cruz C, Greenberg RJ, Justus S, Cinelli L, Humayun MS
doi: 10.1097/IAE.
Macular Diseases
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
BMC Ophthalmol.
Waizel M, Todorova MG, Masyk M, Wolf K, Rickmann A, Helaiwa K, Blanke BR, Szurman P
doi: 10.1186/s12886-017-0471-x.
COMMENTED
Macular Diseases
Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Ophthalmology.
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ
doi: 10.1016/